Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.70 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.70 |
| ▸ | MAOA | P21397 | 2/20 | 0.70 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536868 | 0.95 | MAOB (0.64) | MAOBSCN9AMAOAPARP10 | |
| SCHEMBL5684089 | 0.95 | MAOB (0.67) | MAOBSCN9AMAOAPARP10 | |
| SCHEMBL1070319 | 0.87 | MAOB (0.72) | MAOBSCN9AMAOAPARP10 | |
| SCHEMBL5680157 | 0.87 | MAOB (0.72) | MAOBSCN9AMAOAPARP10 | |
| SCHEMBL1071296 | 0.86 | MAOB (0.74) | MAOBSCN9AMAOAPARP10 | |
| SCHEMBL1070573 | 0.84 | SCN9A (0.73) | MAOBSCN9AMAOAPARP10 | |
| Safinamide SCHEMBL194169 | 0.82 | MAOB (1.00) | MAOBSCN9AMAOA | |
| Safinamide SCHEMBL69350 | 0.82 | MAOB (1.00) | MAOBSCN9AMAOA | |
| Safinamide SCHEMBL31174565 | 0.82 | MAOB (1.00) | MAOBSCN9AMAOA | |
| Safinamide SCHEMBL29358109 | 0.82 | MAOB (1.00) | MAOBSCN9AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| US-8697738-B2 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-15 | — | — | US | claimed |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | NEWRON PHARM SPA (US) | 2013-08-22 | — | — | US | claimed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | claimed |
| EP-1900362-B1 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARM SPA (IT) | 2011-01-12 | — | — | EP | claimed |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | NEWRON PHARMACEUTICALS SPA (IT) | 2010-10-21 | — | — | US | claimed |
| US-7709523-B2 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS SPA (IT) | 2010-05-04 | — | — | US | claimed |
| EP-1658062-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARM SPA (IT) | 2010-02-17 | — | — | EP | claimed |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| EP-1588704-A1 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-26 | — | — | EP | claimed |
| EP-1585510-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-19 | — | — | EP | claimed |
| WO-2005070405-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-08-04 | — | — | WO | claimed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | claimed |
| WO-2005018627-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS, SPA (IT) | 2005-03-03 | — | — | WO | claimed |
| WO-2004062655-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARMACEUTICALS SPA (IT) | 2004-07-29 | — | — | WO | claimed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | claimed |
| US-6303819-B1 | SODIUM CHANNEL-BLOCKING AGENT; CHRONIC OR NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-16 | — | — | US | claimed |
| EP-1044186-A1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-18 | — | — | EP | claimed |
| WO-1999035123-A1 | SUBSTITUTED 2-BENZYLAMINO-2-PHENYL-ACETAMIDE COMPOUNDS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | IL1A, AADAT, DNPEP | MAOB 1206/4885SCN9A 2253/4885MAOA 525/4885 |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | AADAT, PNMT, BCAT2 | MAOB 53/4885SCN9A 946/4885MAOA 58/4885 |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | MVD, TBXA2R, BDKRB2 | MAOB 236/4885SCN9A 1024/4885MAOA 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.